HYDROFLUMETHIAZIDE; RESERPINE - Generic Drug Details
What are the generic sources for hydroflumethiazide; reserpine and what is the scope of patent protection?
Hydroflumethiazide; reserpine
is the generic ingredient in four branded drugs marketed by Usl Pharma, Watson Labs, Ivax Pharms, Par Pharm, and Shire, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.Summary for HYDROFLUMETHIAZIDE; RESERPINE
| US Patents: | 0 |
| Tradenames: | 4 |
| Applicants: | 5 |
| NDAs: | 6 |
| DailyMed Link: | HYDROFLUMETHIAZIDE; RESERPINE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for HYDROFLUMETHIAZIDE; RESERPINE
US Patents and Regulatory Information for HYDROFLUMETHIAZIDE; RESERPINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shire | SALUTENSIN-DEMI | hydroflumethiazide; reserpine | TABLET;ORAL | 012359-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Watson Labs | HYDROFLUMETHIAZIDE AND RESERPINE | hydroflumethiazide; reserpine | TABLET;ORAL | 088110-001 | Mar 22, 1983 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Par Pharm | RESERPINE AND HYDROFLUMETHIAZIDE | hydroflumethiazide; reserpine | TABLET;ORAL | 088907-001 | Sep 20, 1985 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
